SynthesisHuman vaccines & immunotherapeutics2014
Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis.
Synthesis in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Evervac: phase I/II study of immunogenicity and safety of a new adjuvant-free TBE vaccine cultivated in Vero cell culture.Human vaccines & immunotherapeutics · 2020Trial
- Fast-Track to Protection? A Review of Encepur's Express Dosing Schedule for Tick-Borne Encephalitis.Viruses · 2025Review
- Mono-WNV and combined WNV/TBEV inactivated vaccine efficacy against a wide range of WNV and TBEV strains.Frontiers in immunology · 2025Article
- Hard Ticks as Vectors: The Emerging Threat of Tick-Borne Diseases in India.Pathogens (Basel, Switzerland) · 2024Review
- Defining the "Correlate(s) of Protection" to tick-borne encephalitis vaccination and infection - key points and outstanding questions.Frontiers in immunology · 2024Review
- Inapparent Tick-Borne Orthoflavivirus Infection inVaccines · 2023Article
- Development of a novel virus-like particle-based vaccine for preventing tick-borne encephalitis virus infection.Virologica Sinica · 2023Article
- Vaccination against Tick-Borne Encephalitis (TBE) in Italy: Still a Long Way to Go.Microorganisms · 2022Review
- Food-Borne Transmission of Tick-Borne Encephalitis Virus-Spread, Consequences, and Prophylaxis.International journal of environmental research and public health · 2022Review
- A live-attenuated viral vector vaccine protects mice against lethal challenge with Kyasanur Forest disease virus.NPJ vaccines · 2021Article
- Flavivirus Persistence in Wildlife Populations.Viruses · 2021Review
- Experimental Assessment of Possible Factors Associated with Tick-Borne Encephalitis Vaccine Failure.Microorganisms · 2021Article
- Response letter: "Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules".Human vaccines & immunotherapeutics · 2020Article
- Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise.Vaccines · 2020Review
- Exome-wide search and functional annotation of genes associated in patients with severe tick-borne encephalitis in a Russian population.BMC medical genomics · 2019Article
- Comparison of the Immunogenicity and Safety of Two Pediatric TBE Vaccines Based on the Far Eastern and European Virus Subtypes.Advances in virology · 2019Article
- Diagnosing tick-borne encephalitis: a re-evaluation of notified cases.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Experimental Evaluation of the Protective Efficacy of Tick-Borne Encephalitis (TBE) Vaccines Based on European and Far-Eastern TBEV Strains in Mice andFrontiers in microbiology · 2018Article
- Tick-borne encephalitis: What travelers should know when visiting an endemic country.Human vaccines & immunotherapeutics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tick-borne encephalitis (TBE) virus, which is usually divided into European, Far Eastern and Siberian subtypes, is a serious public health problem in several European and Asian countries. Vaccination is the most effective measure to prevent TBE; cross-subtype protection elicited by the TBE vaccines is biologically plausible since all TBE virus subtypes are closely related. This manuscript systematically explores available data on the cross-subtype immunogenicity elicited by the currently available Western vaccines based on the European subtype. Completed immunization course of 3 doses of both Western vaccines determined very high seroconversion/seropositivity rates against both Far Eastern and Siberian subtypes among previously flavivirus-naïve subjects. All but one study found no statistically significant difference in titers of neutralizing antibodies against strains belonging to homologous and heterologous subtypes. Pooled analysis of randomized controlled trials on head-to-head comparison of immunogenicity of Western and Russian TBE vaccines did not reveal differences in seroconversion rates against Far Eastern isolates in either hemagglutination inhibition (risk ratio = 0.98, p = 0.83) or enzyme-linked immunosorbent (risk ratio = 0.95, p = 0.44) assays after 2 vaccine doses. This suggests that, in regions where a heterogeneous TBE virus population circulates, vaccines based on the European subtype may be used alongside vaccines based on the Far Eastern subtype. Studies on the field effectiveness of TBE vaccines and investigation of vaccination failures, especially in countries where different subtypes co-circulate, will further elucidate TBE vaccination-induced cross-subtype protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.